BDBM304216 2-(1-((4- carboxyphenyl)amino)-1- oxo-3-(2- (trifluoromethyl)cyclopropyl) propan-2-yl)-5-(3-chloro- 6-(difluoromethoxy)-2- fluorophenyl)pyridine 1- oxide::BDBM304217::BDBM304218::BDBM304219::US10143681, Example 107

SMILES OC(=O)c1ccc(NC(=O)C(CC2CC2C(F)(F)F)c2ccc(c[n+]2[O-])-c2c(F)c(Cl)ccc2OC(F)F)cc1

InChI Key InChIKey=XAJRJEDITUHVJY-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 304216   

TargetCoagulation factor XI(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM304216(BDBM304218 | BDBM304217 | 2-(1-((4- carboxyphenyl)...)
Affinity DataIC50: 3.20nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM304216(BDBM304218 | BDBM304217 | 2-(1-((4- carboxyphenyl)...)
Affinity DataIC50: 24.2nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM304216(BDBM304218 | BDBM304217 | 2-(1-((4- carboxyphenyl)...)
Affinity DataIC50: 102nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM304216(BDBM304218 | BDBM304217 | 2-(1-((4- carboxyphenyl)...)
Affinity DataIC50: 1.20nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM304216(BDBM304218 | BDBM304217 | 2-(1-((4- carboxyphenyl)...)
Affinity DataIC50: 25.2nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM304216(BDBM304218 | BDBM304217 | 2-(1-((4- carboxyphenyl)...)
Affinity DataIC50: 1.00E+3nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent